174
Views
17
CrossRef citations to date
0
Altmetric
Research Article

Changes in Treatment Volume of Hormonally Treated and Untreated Cancerous Prostate and its Impact on Rectal Dose

, , , &
Pages 10-14 | Published online: 08 Jul 2009

  • Hanks GE, Martz KL, Diamond JJ. The effect of dose on local control of prostate cancer. Int J Radiat Oncol Biol Phys 1988; 15: 1299-305.
  • Dearnaley DP, Khoo VS, Norman AR, et al. Comparison of radiation side effects of conformai and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 1999; 353: 267-72.
  • Zelefsky MJ, Cowen D, Fuks Z, et al. Long term tolerance of high dose three-dimensional conformai radiotherapy in patients with localized prostate carcinoma. Cancer 1999; 85: 2460-8.
  • Hanks GE, Hanlon AL, Pinover WH, et al. Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformai radiotherapy. Cancer J Sci Am 1999; 5: 152-8.
  • Valicenti R, Jiandong JL, Pilepich M, et al. Survival advantage from higher-dose radiation therapy for clinical localized prostate cancer treated on the radiation therapy oncology group trials. J Clin Oncol 2000; 18: 2740-6.
  • Horwitz EM, Hanlon AL, Hanks GE. Update on the treatment of prostate cancer with external beam irradiation. Prostate 1998; 37: 195-206.
  • Shipley WU, Verhey LJ, Munzenrider JE, et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformai protons compared with conventional dose irradiation using photons alone. Int Radiat Oncol Biol Phys 1995; 32: 3-12.
  • Kutcher GJ, Leibel SA, Ling CC, et al. New wine in an old bottle? Dose escalation under dose-volume constraints: a model of conformai therapy of the prostate. Int J Radiat Oncol Biol Phys 1996; 35: 415-6.
  • Boersma LJ, van-den-Brink M, Bruce AM, et al. Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 Gy) conformai radiotherapy for prostate cancer, using dose-volume histograms. Int J Radiat Oncol Biol Phys 1998; 41: 83-92.
  • Dale E, Olsen DR, Fossa SD. Normal tissue complication probabilities correlated with late effects in the rectum after prostate conformai radiotherapy. Int J Radiat Oncol Biol Phys 1999;43:385-91.
  • Yang FE, Chen GT, Ray P, et al. The potential for normal tissue dose reduction with neoadjuvant hormonal therapy in conformai treatment planning for stage C prostate cancer. Int J Radiat Oncol Biol Phys 1995; 33: 1009-17.
  • Forman JD, Kumar R, Haas G, et al. Neoadjuvant hormonal downsizing of localized carcinoma of the prostate: effects on the volume of normal tissue irradiation. Cancer Invest 1995; 13: 8-15.
  • Zelefsky MJ, Harrison A. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy. Urology 1997; 49: 38-45.
  • Lebesque JV, Bruce AM, Kroes AP, et al. Variation in volumes, dose-volume histograms, and estimated normal tissue complication probabilities of rectum and bladder during conformal radiotherapy of T3 prostate cancer. Int J Radiat Oncol Biol Phys 1995; 33: 1109-19.
  • Shearer RJ, Davies JH, Gelister JS, et al. Hormonal cytoreduction and radiotherapy for carcinoma of the prostate. Br J Urol 1992; 69: 521-4.
  • Lavierdiere J, Gomez JL, Cusan L, et al. Beneficial effect of combination hormonal therapy administered prior to and following external radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 1997; 37: 247-52.
  • Lilleby W, Knutsen B, Fossa SD, et al. Computed tomograph/magnetic resonance based volume changes of the primary tumour in patients with prostate cancer with or without androgen deprivation. Radiother Oncol 2000; 57: 193-8.
  • Mostofi FK, Sesterhenn I, Sobin LH. Histological typing of prostate tumours. World Health Organization 1982; 15-23.
  • Lilleby W, Fossa SD, Waehre HR, et al. Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy. Int J Radiat Oncol Biol Phys 1999; 43: 735-43.
  • Zagars GK, Pollack A, Smith LG. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/NO, MO) adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 1999; 44: 809-19.
  • Storey MR, Pollack A, Zagars G, et al. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 2000; 48: 635-42.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.